Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP0N4U)

• Drug Name: PD173074 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Nasopharyngeal carcinoma	2B6B	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 1401
  ChEBI ID: CHEBI:63448
  CAS Number: CAS 219580-11-7
  TTD Drug ID: DMP0N4U

Molecule-Related Drug Atlas

Drug(s) Targeting Fibroblast growth factor receptor (FGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Erdafitinib	DMI782S	Bladder cancer	2C94	Approved	[4]
HIF-1alpha	DM4OQRD	Lymphoma	2A80-2A86	Phase 4	[2]
TAS-120	DMWM4D0	Cholangiocarcinoma	2C12.10	Phase 3	[5]
BGJ398	DMNKBEC	Cholangiocarcinoma	2C12.10	Phase 3	[6]
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[6]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[6]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
BAY1163877	DMCSGJ2	Bladder cancer	2C94	Phase 2	[8]
ICP-192	DM524GR	Bladder cancer	2C94	Phase 2	[9]
PRN1371	DMR7BAO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]

Drug(s) Targeting Proto-oncogene c-Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Chronic myelogenous leukaemia	2A20.0	Approved	[10]
Bosutinib	DMTI8YE	Breast cancer	2C60-2C65	Approved	[10]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[11]
Herbimycin A	DM6YWBF	Solid tumour/cancer	2A00-2F9Z	Approved	[12]
Al3818	DM3WP0N	Alveolar soft part sarcoma	2A60-2C35	Phase 3	[6]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[6]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[13]
KX-01	DMF0NA9	Actinic keratosis	EK90.0	Phase 3	[14]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[15]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor receptor (FGFR)	TT0LF7H	NOUNIPROTAC	Antagonist	[2]
Fusion protein FGFR3-TACC3 (FGFR3-TACC3)	TTFPD8J	FGFR3_HUMAN-TACC3_HUMAN	Inhibitor	[1]
Proto-oncogene c-Src (SRC)	TT6PKBN	SRC_HUMAN	Inhibitor	[3]

References

• [1] Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.Cancer Biol Ther. 2014;15(12):1613-21.
• [2] Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
• [3] Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999;17(2):121-35.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58.
• [8] Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739.
• [9] Clinical pipeline report, company report or official report of InnoCare Pharma.
• [10] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [11] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [12] In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
• [16] Clinical pipeline report, company report or official report of Turning Point Therapeutics.